Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 6/2010

01-11-2010

Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management

Author: Maurie Markman

Published in: Current Oncology Reports | Issue 6/2010

Login to get access

Abstract

Individual randomized phase 3 trials and meta-analyses of previously published studies have provided support for the general concept of the clinical utility of extending the duration of antineoplastic drug therapy in an effort to prolong (“maintain”) a favorable clinical state. This commentary briefly reviews data from several of these reports.
Literature
1.
Maughan TS, James RD, Kerr DJ, et al.: Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 2003, 361:457–464.CrossRefPubMed
2.
Hall GD, Brown JM, Coleman RE, et al.: Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer 2004, 91:621–626.CrossRefPubMed
3.
Varia MA, Stehman FB, Bundy BN, et al.: Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:2849–2855.CrossRefPubMed
4.
Bolis G, Danese S, Tateo S, et al.: Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. Int J Gynecol Cancer 2006, 16(Suppl 1):74–78.CrossRefPubMed
5.
Pfisterer J, Weber B, Reuss A, et al.: Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: A Gynecologic Cancer Intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 2006, 98:1036–1045.CrossRefPubMed
6.
Greene MH, Boice JD Jr, Greer BE, et al.: Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. N Engl J Med 1982, 307:1416–1421.CrossRefPubMed
7.
Travis LB, Curtis RE, Boice JD Jr, et al.: Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996, 56:1564–1570.PubMed
8.
Travis LB, Holowaty EJ, Bergfeldt K, et al.: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999, 340:351–357.CrossRefPubMed
9.
Owonikoko TK, Ramalingam SS, Belani CP: Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clin Cancer Res 2010, 16:2496–2504.CrossRefPubMed
10.
Cappuzzo F, Ciuleanu T, Stelmakh L, et al.: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010, 11:521–529.CrossRefPubMed
11.
Ciuleanu T, Brodowicz T, Zielinski C, et al.: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432–1440.CrossRefPubMed
12.
Muss HB, Case LD, Richards F, et al.: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med 1991, 325:1342–1348.CrossRefPubMed
13.
Markman M, Liu PY, Wilczynski S, et al.: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003, 21:2460–2465.CrossRefPubMed
14.
Markman M, Liu PY, Moon J, et al.: Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol 2009, 114:195–198.CrossRefPubMed
15.
Burger RA, Brady MF, Bookman MA, et al.: Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer: A Gynecologic Oncology Group study. J Clin Oncol 2010, 28(Suppl):LBA1.
16.
Bozcuk H, Artac M, Ozdogan M, Savas B: Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials. Cancer 2005, 104:2650–2657.CrossRefPubMed
17.
Soon YU, Stockler MR, Askie LM, et al.: Duration of chemotherapy for advanced non-small-cell lung cancer: A systemic review and meta-analysis of randomized trials. J Clin Oncol 2009, 27:3277–3283.CrossRefPubMed
18.
Miller KD, Sweeney CJ, Sledge GW Jr: Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001, 19:1195–1206.PubMed
19.
Markman M, Hakes T, Barakat R, et al.: Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. J Clin Oncol 1996, 14:796–799.PubMed
20.
Rohl J, Kushner D, Markman M: Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecol Oncol 2001, 81:201–205.CrossRefPubMed
21.
von Gruenigen V, Karlen JR, Waggoner SE: A case of chronic paclitaxel administration in ovarian cancer. Gynecol Oncol 2003, 89:532–535.CrossRef
22.
Markman M: Viewing ovarian cancer as a "chronic disease": what exactly does this mean? Gynecol Oncol 2006, 100:229–230.CrossRefPubMed
Metadata
Title
Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management
Author
Maurie Markman
Publication date
01-11-2010
Publisher
Current Science Inc.
Published in
Current Oncology Reports / Issue 6/2010
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-010-0121-4

Other articles of this Issue 6/2010

Current Oncology Reports 6/2010 Go to the issue

ReviewPaper

Targeted Signal Transduction Therapies in Myeloid Malignancies

ReviewPaper

Post-Transplantation Lymphoproliferative Disorders: Diagnosis, Prognosis, and Current Approaches to Therapy

ReviewPaper

Should Eligible Patients with T-Cell Lymphoma Receive High-Dose Therapy and Autologous Stem Cell Transplant in the Upfront Setting?

ReviewPaper

State-of-the-art Issues in Hodgkin’s Lymphoma Survivorship

Clinical Trial Report

The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia

ReviewPaper

Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits